Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9446MR)

This product GTTS-WQ9446MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9136MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ12957MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ7286MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ4176MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ6856MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ7987MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ9687MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ7275MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FP3 protein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW